CAS: 6613-44-1; 3,5-Dimethylbenzoyl Chloride

上下游产品

CAS号499-06-9 3,5-二甲基苯甲酸 | CAS号5779-95-3 3,5-二甲基苯甲醛 | CAS号5379-16-8 3,5-二甲基苯乙酮 | CAS号499-06-9 3,5-二甲基苯甲酸 | CAS号142-04-1 苯胺盐酸盐 | CAS号87282-03-9 3,5-dimethyl-N-... | CAS号78710-55-1 3,5-二甲基苄胺 | CAS号112410-23-8 虫酰肼 | CAS号167082-57-7 3,5-bis(chlorom... | CAS号25081-39-4 3,5-二甲基苯甲酸甲酯 | CAS号161050-58-4 甲氧虫酰肼

3,5-二甲基苯甲酸置于n,N-二甲基甲酰胺,草酰氯体系中,用 二氯甲烷 作为反应溶剂,化学反应 0.17H,以100%的收率获得产物3,5-二甲基苯甲酰氯
参考文献:通过主客体阴离子识别进行超分子水凝胶化:用于释放阳离子货物的层状水凝胶材料
标题:通过主客体阴离子识别进行超分子水凝胶化:用于释放阳离子货物的层状水凝胶材料
摘要:由于水中阴离子识别和从头凝胶剂设计具有挑战性,因此由主客体阴离子识别触发的水凝胶很难实现.在这里,我们报告了这样一种水凝胶系统,基于竹[6] Uril 阴离子受体,Bu.尽管bu本身不是凝胶剂,但在碘化物或高氯酸盐的存在下选择性地形成水凝胶.bu负离子识别控制水凝胶,由 NMR,Atr-Ir 和单晶 X 射线表明.通过 Saxs,Cryosem 和全息成像方法阐明了网络结构的凝胶机制和层状性质.流变学表征显示水凝胶稳定且相对坚固.在生理盐水溶液中,水凝胶通过阳离子复分解作用释放阳离子货物,导致凝胶到凝胶的转化.胆碱衍生物作为模型药物,从水凝胶中缓慢释放.我们简单的水凝胶系统可能会启发基于主客体阴离子识别的智能材料的设计,其中特定带电物质的释放或隔离是可取的.
DOI:10.1016/j.Chempr.2021.06.024

专利信息

专利号:US-8742028-B2
优先权日:2009-05-06
标 题:Solid support for Fmoc-solid phase synthesis of peptide acids
发明人：SRIVASTAVA KRIPA S; DAVIS MATTHEW R
权利人:SRIVASTAVA KRIPA S; DAVIS MATTHEW R; MALLINCKRODT LLC
摘要:The present invention provides a solid support for Fmoc-solid phase synthesis of peptides. In particular, the solid supports of the invention may be utilized to produce peptide acids.

专利号:US-4613610-A
优先权日:1984-06-22
标题 :Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
发明人：WAREING JAMES R
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein R1 is C1-6alkyl not containing an asymmetric carbon atom, each of R2 and R5 is independently hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenyl, phenoxy or benzyloxy, each of R3 and R6 is independently hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, each of R4 and R7 is independently hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, with the provisos that not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, not more than one of R2 and R3 is benzyloxy, not more than one of R5 and R6 is trifluoromethyl, not more than one of R5 and R6 is phenoxy, and not more than one of R5 and R6 is benzyloxy, X is -(CH2)m-, -CH=CH-, -CH=CH-CH2- or -CH2-CH=CH-, wherein m is 0, 1, 2 or 3, and Z is wherein R10 is hydrogen or C1-3alkyl, wherein R12 is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, with the provisos that (i) the-X-Z group is in the 4- or 5-position of the pyrazole ring, and (ii) the R1 group and the -X-Z group are ortho to each other, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:US-5354772-A
优先权日:1982-11-22
标 题:Indole analogs of mevalonolactone and derivatives thereof
发明人：KATHAWALA FAIZULLA G
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl-(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, R7b or M, wherein R7b is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and therefore, in the treatment of hyperliopoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.

专利号:US-2016194279-A1
优先权日:2012-12-09
标 题 :One pot process for the conversion of aroyl chlorides to acyl thioureas
发明人：CHEPURI VENKATA RAMANA; BEERAN SENTHILKUMAR
权利人:COUNCIL SCIENT IND RES
摘要:The present invention disclose an improved one pot process for synthesis of acyl thioureas of formula (I), with yield greater than 80%, from aroyl chlorides of formula (I) wherein, R′ is an aryl or a heteroarylene group substituted with one or more groups selected from hydrogen, alkyl, alkylene, alkynyl, alkoxy, alkenyloxy, halo, hydroxyl, nitro, amino, carboxyl, ester, halogenated hydrocarbon or an aryl or heteroaryl; R″ and R′″ are selected independently from hydrogen, alkyl, alkylene, alkynyl, alkoxy, alkenyloxy, halo, hydroxyl, nitro, amino or halogenated hydrocarbon.

专利号:WO-2010129520-A1
优先权日:2009-05-06
标题 :Solid support for fmoc-solid phase synthesis of peptide acids

专利号:CN-103553255-A
优先权日:2013-10-31
标题 :A method for treating and utilizing wastewater in the synthesis of tebufenozide insecticide